US equities |
MU $926.73 ▲+1.38% NVDA $217.25 ▼-1.83% SNDK $1,390.57 ▼-0.91% AMD $561.08 ▼-1.71% SPCX $148.72 ▼-2.26% INTC $95.37 ▼-2.80% AAPL $342.55 ▼-0.12% META $737.36 ▼-0.03%
FinancialContent

Sunshine Biopharma Inc. - Common stock (NQ:SBFM)

0.2209 -0.0221 (-9.09%)
Delayed Quote Updated: 3:55 PM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sunshine Biopharma Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
These stocks are moving in today's session ↗
Via Chartmill
News headline image
Sunshine Biopharma Announces Closing of up to $20.4 Million Public Offering
$6.0 million upfront with an additional $14.4 million of potential aggregate gross proceeds upon the exercise of warrants 
From Sunshine Biopharma Inc.
Via ACCESS Newswire
Top stock movements in today's session. ↗
Via Chartmill
These stocks are making the most noise in today's session. ↗
Via Chartmill
On Thursday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Thursday's session. ↗
Via Chartmill
Thursday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering
From Sunshine Biopharma Inc.
Via ACCESS Newswire
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
Curious about the most active stocks on Wednesday? ↗
Via Chartmill
What's going on in today's session ↗
Via Chartmill
Monday's session: top gainers and losers ↗
Via Chartmill
Keep an eye on the top gainers and losers in Monday's session. ↗
Via Chartmill
Monday's session: gap up and gap down stocks ↗
Via Chartmill
Discover the top movers in Monday's pre-market session. ↗
Via Chartmill
News headline image
Sunshine Biopharma Launches Generic Zofran(R) in Canada, Expanding Oncology Supportive Care Portfolio
Launch introduces ondansetron 4 mg and 8 mg tablets for nausea and vomiting associated with chemotherapy, radiation therapy and surgery Global ondansetron market projected to reach $2.98 billion by... 
From Sunshine Biopharma Inc.
Via ACCESS Newswire
News headline image
Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies
Nanomolar potency against PLpro with broad-spectrum SARS-CoV-2 variants activity Significant dose-dependent suppression of pulmonary viral replication in vivo Strong oral bioavailability and... 
From Sunshine Biopharma Inc.
Via ACCESS Newswire
News headline image
Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions
From Sunshine Biopharma Inc.
Via ACCESS Newswire
News headline image
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:BNTX),(NYSE:AZN),(NASDAQ:MRNA),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
A New Generation of Personalized Cancer Treatments Could Open a Multibillion-Dollar Market for Precision Oncology 
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Sunshine Biopharma Reports In Vivo Tumor Suppression with K1.1 mRNA and Advances Novel mRNA-Cancer Vaccine Strategy for Lung Cancer
From Sunshine Biopharma Inc.
Via ACCESS Newswire
News headline image
Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market
From Sunshine Biopharma Inc.
Via ACCESS Newswire
News headline image
Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market
From Sunshine Biopharma Inc.
Via ACCESS Newswire
News headline image
Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval
From Sunshine Biopharma Inc.
Via ACCESS Newswire
News headline image
Health Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and Vomiting
From Sunshine Biopharma Inc.
Via ACCESS Newswire
News headline image
Sunshine Biopharma and University of Arizona Publish Significant New Research Findings
From Sunshine Biopharma Inc.
Via ACCESS Newswire
News headline image
Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Arimidex(R)
From Sunshine Biopharma Inc.
Via ACCESS Newswire
News headline image
Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R)
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >